Current Research Status and Progress of Tenecteplase in Patients with Acute ST Segment Elevation Myocardial Infarction
Acute myocardial infarction(AMI)is a common and highly prevalent cardiovascular disease,which is one of the important diseases causing death,disability and serious harm to national health.Acute ST segment elevation myocardial infarction(STEMI)is the most severe type of acute coronary syndrome and is the leading cause of death and disability.Emergency percutaneous coronary intervention is the most efficient reperfusion modality for patients with AMI,but it is difficult to completely restore coronary blood flow and microcirculatory perfusion remains suboptimal.Tenecteplase is an extremely high specificity thrombolytic drug characterised by high thrombolytic efficiency,high rate of revascularisation and low risk of bleeding.In recent years,there is an increasing amount of research on intracoronary injection of tenecteplase for STEMI.This article reviews the current research status and progress on tenecteplase in STEMI.
TenecteplaseAcute ST segment elevation myocardial infarctionPercutaneous coronary interventionThrombolytic therapy
万方数据
维普
